TY - JOUR
TI - Campath-1H in B-chronic lymphocytic leukemia: report on a patient
treated thrice in a 3 year period
AU - Pangalis, GA
AU - Dimopoulou, MN
AU - Angelopoulou, MK
AU - Tsekouras, CH
AU - and Siakantaris, MP
JO - Medical Oncology
PY - 2000
VL - 17
TODO - 1
SP - 70-73
PB - STOCKTON PRESS
SN - 1357-0560, 1559-131X
TODO - 10.1007/BF02826220
TODO - Campath-1H; monoclonal antibodies; B-CLL
TODO - Monoclonal antibody (mAb) therapy is a novel alternative treatment for
lymphoid malignancies. in this report we present a 55-year-old patient
with B-chronic lymphocytic leukemia, who was initially treated with
chlorambucil p.o. and subsequently with cyclophosphamide iv with poor
response. Then Campath-1H mAb was administered, He received three cycles
of Campath-1H, over a 3yr period, lasting 12 weeks each, at a final dose
of 30mg weekly, on an outpatient basis. After each cycle of Campath-1H
administration there was a significant decrease of the size of the
palpable lymph nodes, spleen and liver. Restoration of the blood
lymphocyte count to normal and a significant decrease of the bone marrow
lymphocytic infiltration was observed at the end of each cycle.
Therefore, a major clinical response was obtained after all cycles.
Campath-1H administration was well tolerated without causing any serious
toxicity.
ER -